The dynamics of the acute-on-chronic liver failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.
LAS VEGAS, Sept. 7, 2023 /PRNewswire/ -- DelveInsight's Acute-On-Chronic Liver Failure Market Insights report includes a comprehensive understanding of current treatment practices, acute-on-chronic liver failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Acute On Chronic Liver Failure Market Report
- As per DelveInsight analysis, the acute-on-chronic liver failure market size in the 7MM was found to be~USD 71 million in 2020 and it is expected to grow positively at a significant CAGR during the study period (2019-2032).
- As per DelveInsight analysts, the total cases of acute-on-chronic liver failure were ~61K in the 7MM in 2020.
- Globally, leading acute-on-chronic liver failure companies such as Grifols Therapeutics LLC, Promethera Biosciences, GENFIT, Akaza Bioscience, RHEACELL, Versantis, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., and others are developing novel acute-on-chronic liver failure drugs that can be available in the acute-on-chronic liver failure market in the coming years.
- Some key therapies for acute-on-chronic liver failure treatment include SMT + PE-A 5%, HepaStem, Nitazoxanide (NTZ), TAK-242, APZ2, VS-01, and others.
Discover which therapies are expected to grab the major acute-on-chronic liver failure market share @ Acute-On-Chronic Liver Failure Market Report
Acute-On-Chronic Liver Failure Overview
Acute-on-chronic liver failure (ACLF) is a severe medical condition characterized by the sudden deterioration of liver function in individuals who already have an underlying chronic liver disease. This condition is marked by a rapid and often life-threatening progression of symptoms, requiring immediate medical attention. The causes of ACLF are diverse, with the most common trigger being an acute insult, such as viral hepatitis, excessive alcohol consumption, drug-induced liver injury, or bacterial infections. These acute insults can exacerbate an existing chronic liver condition, leading to a cascade of events that disrupt liver function and cause widespread complications.
Symptoms of ACLF can vary in severity but often include jaundice (yellowing of the skin and eyes), abdominal pain, easy bruising or bleeding, confusion, and fluid accumulation in the abdomen and legs. Due to the rapid nature of the condition, individuals with ACLF can experience a sudden onset of these symptoms, often leading to hospitalization. Diagnosing ACLF involves a combination of clinical assessment, medical history, physical examination, and laboratory tests. Blood tests may reveal elevated levels of liver enzymes, bilirubin, and markers of inflammation. Imaging techniques like ultrasound, CT scans, or MRI might be used to assess the extent of liver damage and identify potential causes. In some cases, a liver biopsy might be performed to assess the severity of liver injury.
Acute-On-Chronic Liver Failure Epidemiology Segmentation
The acute-on-chronic liver failure epidemiology section provides insights into the historical and current acute-on-chronic liver failure patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The acute-on-chronic liver failure market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Total ACLF Prevalent Cases
- ACLF Diagnosed Prevalent Cases
- ACLF Gender-Specific Diagnosed Prevalent Cases
- ACLF Diagnosed And Treatable Cases
Acute-On-Chronic Liver Failure Treatment Market
The acute-on-chronic liver failure treatment is a complex and multifaceted endeavor that aims to address both the acute deterioration of liver function and the underlying chronic liver disease. ACLF is a life-threatening condition often characterized by the rapid development of organ failure, necessitating immediate medical attention. The primary goals of ACLF treatment are to stabilize the patient's condition, manage complications, and improve liver function whenever possible. This often involves a combination of supportive care, such as close monitoring of vital signs, correction of electrolyte imbalances, and management of infections, which can be common due to compromised immune function in these patients. Nutritional support plays a vital role, as malnutrition is common in ACLF and can contribute to poor outcomes.
Additionally, addressing the underlying chronic liver disease through interventions like alcohol cessation programs, antiviral therapy for hepatitis, or management of cirrhosis-related complications is crucial. For those with severe liver dysfunction and a poor prognosis, a liver transplant might be considered, offering a chance for recovery and improved quality of life. The acute-on-chronic liver failure treatment approach requires a multidisciplinary team of hepatologists, intensivists, infectious disease specialists, and nutritionists to tailor a comprehensive and personalized strategy for each patient's unique condition. Collaboration among these specialists is essential to manage the intricate medical challenges posed by ACLF effectively. Ongoing research continues to refine our understanding of ACLF and its treatment strategies, aiming to improve outcomes and ultimately save lives threatened by this serious condition.
To know more about acute-on-chronic liver failure treatment, visit @ Acute-On-Chronic Liver Failure Treatment Drugs
Key Acute-On-Chronic Liver Failure Therapies and Companies
- SMT + PE-A 5%: Grifols Therapeutics LLC
- HepaStem: Promethera Biosciences
- Nitazoxanide (NTZ): GENFIT
- TAK-242: Akaza Bioscience
- APZ2: RHEACELL
- VS-01: Versantis
Learn more about the FDA-approved drugs for acute-on-chronic liver failure @ Drugs for Acute-On-Chronic Liver Failure Treatment
Acute-On-Chronic Liver Failure Market Dynamics
The acute-on-chronic liver failure market dynamics reflect a complex interplay of medical advancements, healthcare infrastructure, and patient demographics. The global ACLF market is witnessing growth due to an increasing prevalence of chronic liver diseases, such as cirrhosis and hepatitis, which serve as underlying factors for ACLF development. As healthcare systems evolve and diagnostic capabilities improve, early detection and timely intervention are becoming more feasible, thereby driving the demand for ACLF treatment options.
Pharmaceutical companies are investing in research and development to introduce novel therapies that target the multifactorial aspects of ACLF, ranging from inflammation and immune dysregulation to organ failure. Additionally, the acute-on-chronic liver failure market is influenced by factors such as regulatory policies, reimbursement frameworks, and patient awareness, all of which collectively shape the landscape for ACLF management and treatment modalities.
While the increasing prevalence of chronic liver diseases fuels ACLF market expansion, several barriers can impede its progress. Limited awareness among both healthcare professionals and patients about ACLF's distinct characteristics and proper management can lead to underdiagnosis and delayed treatment. Additionally, the high cost of advanced therapies and the complex nature of ACLF often pose financial challenges for patients and healthcare systems alike, impacting the adoption of novel treatments.
Regulatory hurdles and stringent clinical trial requirements can slow down the approval process for new therapies. Moreover, the intricate pathophysiology of ACLF presents challenges in developing targeted and effective interventions. Overcoming these barriers necessitates collaborative efforts between healthcare stakeholders, regulatory authorities, and the pharmaceutical industry to ensure timely diagnosis, affordability, and accessibility of treatments for ACLF.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Acute-On-Chronic Liver Failure Market Size in 2020 | USD 71 Million |
Key Acute-On-Chronic Liver Failure Companies | Grifols Therapeutics LLC, Promethera Biosciences, GENFIT, Akaza Bioscience, RHEACELL, Versantis, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., and others |
Key Acute-On-Chronic Liver Failure Therapies | SMT + PE-A 5%, HepaStem, Nitazoxanide (NTZ), TAK-242, APZ2, VS-01, and others |
Scope of the Acute-On-Chronic Liver Failure Market Report
- Therapeutic Assessment: Acute-On-Chronic Liver Failure current marketed and emerging therapies
- Acute-On-Chronic Liver Failure Market Dynamics: Conjoint Analysis of Emerging Acute-On-Chronic Liver Failure Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Acute-On-Chronic Liver Failure Market Access and Reimbursement
Discover more about acute-on-chronic liver failure drugs in development @ Acute-On-Chronic Liver Failure Clinical Trials
Table of Contents
1. | Acute-On-Chronic Liver Failure Market Key Insights |
2. | Acute-On-Chronic Liver Failure Market Report Introduction |
3. | Acute-On-Chronic Liver Failure Market Overview at a Glance |
4. | Acute-On-Chronic Liver Failure Market Executive Summary |
5. | Disease Background and Overview |
6. | Acute-On-Chronic Liver Failure Treatment and Management |
7. | Acute-On-Chronic Liver Failure Epidemiology and Patient Population |
8. | Patient Journey |
9. | Acute-On-Chronic Liver Failure Marketed Drugs |
10. | Acute-On-Chronic Liver Failure Emerging Drugs |
11. | Seven Major Acute-On-Chronic Liver Failure Market Analysis |
12. | Acute-On-Chronic Liver Failure Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Acute-On-Chronic Liver Failure Pipeline
Acute-On-Chronic Liver Failure Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute-on-chronic liver failure companies, including Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT, among others.
Acute-On-Chronic Liver Failure Epidemiology
Acute-On-Chronic Liver Failure Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the acute-on-chronic liver failure epidemiology trends.
Acute Liver Failure Market
Acute Liver Failure Market Insights, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute liver failure companies, including Promthera Biosciences, Akava Biosceinces, Ticeba GmbH, Tianjin Weikai Bioeng., Ltd, HLB Cell Co., Ltd., among others.
Acute Liver Failure Pipeline
Acute Liver Failure Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute liver failure companies, including Promthera Biosciences, Akava Biosceinces, Ticeba GmbH, Tianjin Weikai Bioeng., Ltd, HLB Cell Co., Ltd., among others.
Alpha Thalassemia Market
Alpha Thalassemia Market Insights, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key alpha thalassemia companies, including CRISPR Therapeutics, Agios Pharmaceuticals, DisperSol Technologies, Celgene, EmeraMed, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/acute-on-chronic-liver-failure-market-to-register-immense-growth-by-2032-assesses-delveinsight--key-companies---grifols-promethera-genfit-rheacell-versantis-martin-gni-group-301920279.html
